AhR Inhibitors
1 drugsAbout AhR
The Aryl hydrocarbon receptor (AhR) is a ligand-activated transcription factor mediating the effects of environmental contaminants and endogenous compounds, influencing cellular processes.
AhR has therapeutic potential in immunology, as evidenced by the FDA-approved drug VTAMA, though no genetic evidence directly links AhR to specific diseases.
AhR is currently targeted by one FDA-approved drug, VTAMA (Merck), a small molecule used in immunology.
Top AhR Drugs
Merck is the only company with an approved drug targeting AhR.
The lack of competitors suggests high barriers to entry or untapped market potential.
AhR Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets AhR, using small molecule modality.
Exploring alternative modalities like antibodies or peptides could provide differentiation.
AhR Clinical Trials 19 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on AhR. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 1 | 1 | 0 | 0 | 100% |
| Phase 2 | 4 | 2 | 0 | 2 | 100% |
| Phase 3 | 9 | 8 | 0 | 0 | 100% |
| Phase 4 | 5 | 3 | 0 | 2 | 100% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
AhR Drug Approval Timeline (2022 - 2022)
The first and only drug targeting AhR, VTAMA, was approved in 2022.
The recent approval suggests a renewed interest in AhR as a drug target.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 8 (3 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on AhR. A trial counts if an approved drug acting on AhR is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.